A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Arch Neurol 63:49-54, Reisberg,B.,et al, 2006
Effect of Enhanced Psychosocial Care on Antipsychotic Use in Nursing Home Residents with Severe Dementia; Cluster Randomised Trial
BMJ 332:756-758,741, Fossey,J.,et al, 2006
Donepezil in Patients with Severe Alzheimers Disease: Double-Blind, Parallel-Group, Placebo-Controlled Study
Lancet 367:1057-1065,1031, Winblad,B.,et al, 2006
Mild Cognitive Impairment
Lancet 367:1262-1270, Gauthier,S.,et al, 2006
Cholinesterase Inhibitors for Patients with Alzheimers Disease: Systematic Review of Randomised Clinical Trials
BMJ 331:321-323, Kaduszkiewicz,H.,et al, 2005
Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia, Meta-analysis of Randomized Placebo-Controlled Trials
JAMA 294:1934-1943,1963, Schneider,L.S.,et al, 2005
Lipid Lowering Agents Are Associated With a Slower Cognitive Decline in Alzheimers Disease
JNNP 76:1624-1629, Masse,I.,et al, 2005
Global Prevalence of Dementia: A Delphi Consensus Study
Lancet 366:2112-2117, Ferri,C.P.,et al, 2005
A-beta Vaccination Effects on Plaque Pathology in the Absence of Encephalitis in Alzheimer Disease
Neurol 64:129-131,10, Masliah,E.,et al, 2005
Bone Mineral Density and the Risk of Alzheimer Disease
Arch Neurol 62:107-111, Tan,Z.S.,et al, 2005
A 32-Year Prospective Study of Change in Body Weight and Incident Dementia
Arch Neurol 62:55-60,20, Stewart,R.,et al, 2005
Genetic Factors in Alzheimer's Disease
NEJM 352: 862-863, 884, Bird, T., 2005
Unawareness of Cognitive Deficit (Cognitive Anosognosia) in Probable AD and Control Subjects
Neurol 64:693-699, Barrett, A.M., et al, 2005
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy
Arch Neurol 62:721-728, Mega,M.S.,et al, 2005
Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease
Arch Neurol 62:753-757, Sparks,D.L.,et al, 2005
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
NEJM 352:2379-2388,2439, Petersen,R.C.,et al, 2005
Neurologic Manifestations in Welders with Pallidal MRI T1 Hyperintensity
Neurol 64:2033-2039,2001, Josephs,K.A.,et al, 2005
Reduced Risk of Alzheimer Disease in Users of Antioxidant Vitamin Supplements
Arch Neurol 61:82-88, Zandi,P.P.,et al, 2004
Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil, A Randomized Controlled Trial
JAMA 291:317-324, Tariot,P.N.,et al, 2004
Imaging Cerebral Atrophy:Normal Ageing to Alzheimer's Disease
Lancet 363:392-394, Fox,N.C.&Schott,J.M., 2004
Comparison of Different MRI Brain Atrophy Rate Measures with Clinical Disease Progression in AD
Neurol 62:591-600, Jack, Jr.,C.R.,et al, 2004
Diabetes Mellitus and Risk of Alzheimer Disease and Decline in Cognitive Function
Arch Neurol 61:661-666, Arvanitakis,Z.,et al, 2004
Size of the Treatment Effect on Cognition of Cholinesterase Inhibition in Alzheimer's Disease
JNNP 75:677-685, Rockwood,K., 2004
Estimating Prognosis for Nursing Home Residents with Advanced Dementia
JAMA 291:2734-2740, Mitchell,S.L.,et al, 2004
Alzheimer's Disease
NEJM 351:56-67, Cummings,J.L, 2004
The Efficacy of Donepezil in the Treatment of Neuropsychiatric Symptoms in Alzheimer Disease
Neurol 63:214-219,200, Holmes,C.,et al, 2004
Atypical Antipsychotic Drugs in the Treatment of Behavioural and Psychological Symptoms of Dementia: Systematic Review
BMJ 329:75-78, Lee,P.E.,et al, 2004
Long-term Donepezil Treatment in 565 Patients with Alzheimer's Disease (AD2000): Randomised Double-Blind Trial
Lancet 363:2105-2115,2100, AD2000 Collaborative Group, 2004
Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women
JAMA 291:2947-2958,3005, Shumaker,S.A.,et al, 2004
Economic Evaluation of Donepezil in Moderate to Severe Alzheimer Disease
Neurol 63:644-650, Feldman,H.,et al, 2004
Efficacy of Donepezil in Mild Cognitive Impairment
Neurol 63:651-657, Salloway,S.,et al, 2004
Driver Route-Following and Safety Errors in Early Alzheimer Disease
Neurol 63:832-837, Uc,E.Y.,et al, 2004
A Multimodal Assessment of Driving Performance in HIV Infection
Neurol 63:1417-1422, Marcotte,T.D.,et al, 2004
Progressive Posterior Cortical Dysfunction
Neurol 63:1175-1180, Renner,J.A.,et al, 2004
Clinical, Genetic, and Neuropathologic Characteristics of Posterior Cortical Atrophy
Neurol 63:1168-1174, Tang-Wai,D.F.,et al, 2004
Hyperinsulinemia and Risk of Alzheimer Disease
Neurol 63:1187-1192, Luchsinger,J.A.,et al, 2004
Memory Complaints in Nondemented Men Predict Future Pathologic Diagnosis of Alzheimer Disease
Neurol 63:1960-1961, Jorm,A.F.,et al, 2004
Mixed Dementia, Emerging Concepts and Therapeutic Implications
JAMA 292:2901-2908, Langa,K.M.,et al, 2004
Preclinical Alzheimer Disease
Neurol 63:2341-2347, Saxton,J.,et al, 2004
Neuro-Ophthalmic Findings in the Visual Variant of Alzheimers Disease
Ophthalmology 111:376-381, Lee,A.G. &Martin,C.O., 2004
Potentially Reversible Autoimmune Limbic ncephalitis with Neuronal Potassium Channel Antibody
Neurol 62:1177-1182,1040, Thieben,M.J.,et al, 2004
The Topography of Metabolic Deficits in Posterior Cortical Atrophy (the Visual Variant of Alzheimers Disease) with FDG-PET
JNNP 74:1521-1529, Nestor,P.J.,et al, 2003
Tolerability of Memantine in Combination with Cholinesterase Inhibitors in Dementia Therapy
Int Clin Psychopharm 18:81-85, Hartmann,S.& Mobius, H.J., 2003
Efficacy of Cholinesterase Inhibitors in the Treatment of Neuropsychiatric symptoms and Functional Impairment in Alzheimer Disease
JAMA 289:210-216, Trinh,N.,et al, 2003
Acetylcholinesterase Inhibitors for Vascular Dementia and Alzheimer's Disease Combined With Cerebrovascular Disease
Stroke 34:584-586, Bowler,J.V., 2003
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Arch Neurol 60:203-208, Luchsinger,J.A.,et al, 2003
Low Blood Pressure and Risk of Dementia in the Kungsholmen Project
Arch Neurol 60:223-228, Qiu,C.,et al, 2003
Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases
Arch Neurol 60:337-341, 320, Zarow,C.,et al, 2003